These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Qi YT; Hou Y; Qi LC Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164 [TBL] [Abstract][Full Text] [Related]
5. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Chaudhary P; Gajra A Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):156-63. PubMed ID: 20446909 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240 [TBL] [Abstract][Full Text] [Related]
9. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
10. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897 [TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Shah RR; Shah DR Drug Saf; 2019 Feb; 42(2):181-198. PubMed ID: 30649743 [TBL] [Abstract][Full Text] [Related]
12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152 [TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039 [TBL] [Abstract][Full Text] [Related]
15. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825 [TBL] [Abstract][Full Text] [Related]
16. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Kashiwabara K; Semba H; Fujii S; Tsumura S Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074 [TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer. Thomas M Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409 [TBL] [Abstract][Full Text] [Related]
20. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]